Mineralys Therapeutics (MLYS) announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat in patients with confirmed uncontrolled hypertension ...

Mineralys Therapeutics has a twelve month low of $8.24 and a twelve month high of $18.38. The firm has a market cap of $756.56 million, a P/E ratio of -3.31 and a beta of -0.39.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) saw strong trading volume on Wednesday after HC Wainwright raised their price target on the stock from $30.00 to $42.00.HC Wainwright ...

Soon, it may be possible to layer in a therapy from Mineralys Therapeutics – with a new mechanism of action – to help regain control. That is the conclusion of the Advance-HTN study reported ...

RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension ...

RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for conditions related to dysregulated aldosterone, announced it will host a conference ...

In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stands against other stocks that are receiving the most insider investment in March. “The economy ...

(MENAFN- GlobeNewsWire - Nasdaq) RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical ...

We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stands against ...